Summary
Female C57/Bl/6 mice (6–8 weeks old) bearing the Lewis or the MBL-2 tumor received localized tumor irradiation (1,600 rad; Cobalt 60) 3 days after tumor implantation. We compared the effects of the association of irradiation and immuno-BCG-F (1 mg/mouse i.v.) against three control groups (no treatment, irradiation alone, immuno-BCG-F alone). The frequency and number of BCG injections were varied in the different subgroups. Result were improved in the Lewis tumor system when BCG was injected just after the end of the irradiation. Efficiency improved with increasing number of injections (P<0.05). In the MBL-2 system, depending on the timing of BCG injections, we observed significant prolongation of survival (irradiation + BCG) over that in control groups.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bekesi, J. G., Holland, J. F.: Combined chemotherapy and immunotherapy of transplantable and spontaneous murine leukemia in DBA/2 and AKR mice. In: Recent Results in Cancer Research. Investigation and Stimulation of Immunity in Cancer Patients. Mathe, G., Weiner, R. (eds.), p. 357. New York: Springer 1974
Dubois, J. B., Serrou, B.: Treatment of the mouse Lewis tumor by the association of radiotherapy and immunotherapy with Bacillus Calmette-Guérin. Cancer Res. 36, 1731 (1976)
Gutterman, J. U., Mavligit, G., Gottlieb, J. A., Burgess, M. A., MacBride, D. E., Einhorn, L., Freireich, E. J., Hersh, E. M.: Chemoimmunotherapy of disseminated malignant melanoma with Dimethyl-Triazeno-imidazole carboxamide and Bacillus Calmette-Guérin. New Engl. J. Med. 291, 592 (1974)
Hiu, I. J., Amiel, J. L.: Isolation of immunological adjuvant component from BCG cells. Rev. Europ. Et. Clin. Biol. 16, 55 (1971)
Martin, M., Bourut, C., Halle-Panenko, O., Mathé, G.: Immunotherapy of Lewis tumor residual disease left by local radiotherapy. Biomedicine 23, 237 (1975)
Mathé, G.: Attempt at using systemic immunity adjuvants in experimental and human cancer therapy. In: Immunopotentiation. Ciba Foundation Symposium. Knight, J. (ed.), p. 305. Amsterdam: Associated Scientific Publishers 1973
Mathé, G., Kamel, M., Dezfulian, M., Halle-Panenko, O., Bourut, C.: An experimental screening for “systemic adjuvants of immunity” applicable in cancer immunotherapy Cancer Res. 33, 1987 (1973)
Pearson, J. W., Pearson, G. R., Gibson, W. T., Chermann, J. C., Chirigos, M. A.: Combined chemoimmunostimulation therapy against murine leukemia. Cancer Res. 32, 904 (1972)
Serrou, B., Dubois, J. B.: Combination of radiotherapy and immunotherapy in the treatment of Lewis's tumour. Europ. J. Cancer 13, 489 (1977)
Song, C. W., Levitt, S. H.: Immunotherapy with neuraminidase treated tumor cells after radiotherapy. Radiat. Res. 64, 485 (1975)
Zbar, B.: Specific and non-specific immunotherapy: use of BCG. In: Recent Results in Cancer Research. Investigation and Stimulation of Immunity in Cancer Patients. Mathé, G., Weiner, R. (eds.), p. 350. New York: Springer 1974
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Serrou, B., Dubois, J.B., Andress, D. et al. Efficacy of BCG treatment after local radiotherapy in Lewis and MBL-2 tumor-bearing mice. Cancer Immunol Immunother 4, 209–214 (1978). https://doi.org/10.1007/BF00204742
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00204742